Glucosamine Enhances TRAIL-Induced Apoptosis in the Prostate Cancer Cell Line DU145

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells.
• TRAIL resistance is a significant clinical challenge, necessitating sensitizing agents.
• Glucosamine (GlcN) is investigated for its potential to overcome TRAIL resistance.

Purpose of the Study:

• To investigate if glucosamine (GlcN) sensitizes cancer cells to TRAIL-induced apoptosis.
• To elucidate the molecular mechanisms underlying GlcN's sensitizing effects.
• To assess the impact of GlcN and TRAIL combination on inflammatory responses.

Main Methods:

• Immunoblotting, flow cytometry, confocal microscopy, qPCR, and caspase activity assays were employed.
• DU145 cancer cells were treated with GlcN and TRAIL, individually and in combination.
• Analysis focused on apoptosis markers, death receptor expression, apoptotic pathway activation, and inflammatory signaling.

Main Results:

• GlcN sensitized DU145 cells to TRAIL-induced apoptosis without increasing death receptor 5 (DR5) expression.
• The combination therapy activated both extrinsic and intrinsic apoptotic pathways, evidenced by caspase cleavage.
• GlcN/TRAIL suppressed anti-apoptotic factors (cFLIP, BCL-XL, MCL-1, XIAP) and promoted BAK translocation.
• GlcN pretreatment attenuated TRAIL-induced inflammation by reducing NF-kB signaling and downstream gene expression (IL-6, IL-8).

Conclusions:

• The combination of Glucosamine (GlcN) and TRAIL is a promising strategy for cancer treatment.
• This combination effectively overcomes TRAIL resistance by enhancing apoptosis.
• GlcN/TRAIL also abrogates TRAIL-induced inflammatory responses, potentially improving clinical outcomes.